Innovation without boundaries, growth with resilience. After nearly six months of evaluation and review, the Deloitte Greater Bay Area Technology Fast 40 & Rising Star Program, jointly launched by Deloitte China and key institutions across the Greater Bay Area, concluded with a grand award ceremony today. In recognition of its outstanding innovation capability, commercialization strength, and future growth potential, Great Bay Bio was honored as one of the Greater Bay Area Technology Fast 40 companies.

▲ Mr. Kingsley Leung, Co-founder and Chairman of Great Bay Bio, attended the award ceremony

The Deloitte Greater Bay Area Technology Fast 40 & Rising Star Program is led by Deloitte China in collaboration with the Greater Bay Area Technology Innovation Service Center and the Guangdong Institute of the Greater Bay Area, with guidance from official authorities including the Guangzhou Municipal Science and Technology Bureau. Combining the authority of leading professional institutions with strong regional governmental support, the program is recognized as one of the most influential and valuable benchmarks for high-growth technology enterprises in the Greater Bay Area.

The selection process applies rigorous criteria across multiple dimensions, including the strength of the founding team, technological innovation, business model, financial performance, and long-term sustainability. As the Greater Bay Area sub-program of Deloitte’s global benchmark initiative for high-growth technology companies, it reflects both professional credibility and broad market recognition.

This year’s award event also featured a Greater Bay Area Entrepreneurs Exchange Tour, providing an opportunity for outstanding entrepreneurs from different industries to connect and engage in meaningful exchange. The program included in-depth visits to Hong Kong’s innovation ecosystem, covering key institutions such as the Hong Kong Stock Exchange, Invest Hong Kong, Hong Kong Science Park, and The Chinese University of Hong Kong. Through high-value exchange and resource connection, the initiative aims to support companies in expanding from regional innovators to global contenders.

This recognition reflects the high regard Great Bay Bio has earned from respected professional institutions, regional authorities, and industry capital communities for its innovation capability, commercialization potential, and future growth prospects.

Great Bay Bio has pioneered the cross-disciplinary application of cutting-edge technologies such as AI in the field of bioprocessing, driving transformative advances in the industry. Through long-term collaborations with clients worldwide and multiple leading multinational companies, Great Bay Bio is helping address key challenges in global drug development, including long development timelines, high costs, and low success rates.

This award marks a new milestone for Great Bay Bio. Building on this recognition from Deloitte China and partners across the ecosystem, the company will continue to deepen the integration of AI and bioprocess innovation, strengthen investment in core technology development, and accelerate the translation of innovation into practical value—making global biologics development simpler, faster, and more efficient.